TG Therapeutics Plans Cut-Price Challenger To Ocrevus In MS

Filing Expected In Q3

TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.

Brain with MS — An MRI of the brain of an MS patient, yellow-gold-orange showing areas of demyelination. • Source: Alamy

Roche’s multiple sclerosis blockbuster Ocrevus looks set to face new competition from a rival CD20 targeting antibody from TG Therapeutics – who are willing to offer their drug at a significant discount, once approved.

TG Therapeutics’ challenger is ublituximab, which like Ocrevus (ocrelizumab) is an intravenously administered CD20 targeting antibody and is now set to be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

China Biopharma Podcast - 14 May 2025 (Chinese Language)

14 May 2025

• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

13 May 2025

• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.